Swapnil Potdar
Swapnil Potdar
Bioinformatician, Institute for Molecular Medicine, Finland
Verified email at helsinki.fi
Title
Cited by
Cited by
Year
Prediction of drug combination effects with a minimal set of experiments
A Ianevski, AK Giri, P Gautam, A Kononov, S Potdar, J Saarela, ...
Nature machine intelligence 1 (12), 568-577, 2019
352019
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
E Skaga, E Kulesskiy, A Fayzullin, CJ Sandberg, S Potdar, A Kyttälä, ...
BMC cancer 19 (1), 1-14, 2019
282019
Breeze: an integrated quality control and data analysis application for high-throughput drug screening
S Potdar, A Ianevski, JP Mpindi, D Bychkov, C Fiere, P Ianevski, B Yadav, ...
Bioinformatics 36 (11), 3602-3604, 2020
262020
Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
JP Mpindi, P Swapnil, B Dmitrii, S Jani, K Saeed, K Wennerberg, ...
Bioinformatics 31 (23), 3815-3821, 2015
252015
ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors
K Kaipio, P Chen, P Roering, K Huhtinen, P Mikkonen, P Östling, ...
The Journal of pathology 250 (2), 159-169, 2020
172020
Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas
BA Brodin, K Wennerberg, E Lidbrink, O Brosjö, S Potdar, JN Wilson, ...
British journal of cancer 120 (4), 435-443, 2019
142019
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
PO Pietarinen, CA Eide, P Ayuda-Durán, S Potdar, H Kuusanmäki, ...
Oncotarget 8 (14), 22606, 2017
112017
Human Tumor–Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing
K Tuomainen, A Al-Samadi, S Potdar, L Turunen, M Turunen, ...
Cancers 12 (1), 92, 2020
92020
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment
E Skaga, E Kulesskiy, M Brynjulvsen, CJ Sandberg, S Potdar, ...
Clinical and translational medicine 8 (1), 1-15, 2019
72019
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
S Adnan-Awad, D Kim, H Hohtari, KK Javarappa, T Brandstoetter, I Mayer, ...
Leukemia 35 (7), 1964-1975, 2021
52021
BCR-ABL1 p190 in CML: a minor breakpoint with a major impact
SA Awad, H Hohtari, KK Javarappa, T Brandstoetter, D Kim, S Potdar, ...
Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019
42019
Receptor tyrosine kinase signaling networks define sensitivity to ERBB inhibition and stratify KRAS-mutant lung cancers
SS Talwelkar, AS Nagaraj, JR Devlin, A Hemmes, S Potdar, EA Kiss, ...
Molecular cancer therapeutics 18 (10), 1863-1874, 2019
42019
Comparative Analysis of independent ex vivo functional drug screens identifies predictive biomarkers of BCL-2 inhibitor response in AML
BS White, SA Khan, S Potdar, MJ Mason, CE Tognon, BJ Druker, ...
Blood 132, 2763, 2018
22018
Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular …
D Malani, A Kumar, B Yadav, M Kontro, S Potdar, S Eldfors, J Saarela, ...
Blood, The Journal of the American Society of Hematology 130 (Suppl_1), 854-854, 2017
22017
A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland
J Saarela, E Kulesskiy, K Laamanen, T Pemovska, V Pietiäinen, S Potdar, ...
Synergy 1 (1), 78, 2014
22014
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
BS White, SA Khan, MJ Mason, S Potdar, D Malani, H Kuusanmäki, ...
NPJ precision oncology 5 (1), 1-11, 2021
12021
PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naïve prostate cancer
S Blom, P Mäki-Teeri, A Erickson, L Paavolainen, T Mirtti, A Rannikko, ...
Cancer Research 77 (13 Supplement), 5732-5732, 2017
12017
Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments
SS Talwelkar, MI Mäyränpää, L Søraas, S Potdar, J Bao, A Hemmes, ...
Cell Reports Medicine 2 (8), 100373, 2021
2021
High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma
K Tuomainen, A Hyytiäinen, A Al-Samadi, P Ianevski, A Ianevski, S Potdar, ...
Scientific Reports 11 (1), 1-10, 2021
2021
High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome
M Jamshidi, R Fagerholm, TA Muranen, S Kaur, S Potdar, S Khan, E Netti, ...
Cancers 13 (12), 2907, 2021
2021
The system can't perform the operation now. Try again later.
Articles 1–20